

Annex B: VIS candidates

Category	Candidate	Likely Vaccination Strategy	Licensure Status
Vaccines for endemic disease prevention through routine immunisation	Diphtheria	<i>Routine Diphtheria-containing Booster</i>	Licensed
	Tetanus	<i>Routine Tetanus Toxoid-containing Booster</i>	Licensed
	Pertussis	<i>Routine Pertussis-containing Booster</i>	Licensed
	Hepatitis B	<i>Birth Dose</i>	Licensed
	Oral cholera vaccine	<i>Preventive Campaigns in Endemic Settings</i>	Licensed
	Meningitis C, Y, W, X	<i>Multivalent Conjugate Vaccines in Routine & Campaigns</i>	Licensed
	Hepatitis E	<i>Campaigns in Humanitarian Settings</i>	Licensed
	Hepatitis A	<i>Routine Immunisation</i>	Licensed
	Dengue	<i>Routine Immunisation</i>	Licensed
	Influenza	<i>Routine Maternal Immunisation</i>	Licensed
	RSV	<i>Routine Maternal Immunisation</i>	Under Development (Phase 3)
	RSV mAb	<i>Prophylactic Neonatal Use in High-risk Populations</i>	Licensed
	Rabies	<i>Post-exposure Prophylaxis</i>	Licensed
	Rabies Ig/mAb	<i>Post-exposure Prophylaxis</i>	Licensed (mAb in development)
Malaria (RTS,S)	<i>Implementation Pilot Phase 2; Future Routine Use</i>	Licensed (Implementation pilots)	
Vaccine investments for epidemic preparedness	Chikungunya	<i>Outbreak Response</i>	Under Development (Phase 2)
	Zika virus	<i>Outbreak Response</i>	Under Development (Phase 2)
	Ebola	<i>Outbreak Response</i>	Under Development (Phase 3)
	Influenza	<i>Pandemic Response</i>	Licensed
IPV	IPV post-eradication	<i>Routine Immunisation</i>	Licensed